AKCEA-APOCIII-LRx Development, Manufacture and Commercialization License. Subject to the terms and conditions of this Agreement, upon Novartis’ exercise of the Option for AKCEA-APOCIII-LRx in accordance with ARTICLE 3 and Novartis’ payment of the license fee under Section 7.2, Akcea grants to Novartis a worldwide, exclusive, royalty-bearing, sublicensable (in accordance with Section 5.2) license under the Licensed Technology to Research, Develop, Manufacture, have Manufactured and Commercialize AKCEA-APOCIII-LRx.
Appears in 4 contracts
Samples: Strategic Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc), Strategic Collaboration, Option and License Agreement (Akcea Therapeutics, Inc.), Strategic Collaboration, Option and License Agreement (Akcea Therapeutics, Inc.)
